These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 25536671)

  • 1. Fecal calprotectin: towards a standardized use for inflammatory bowel disease management in routine practice.
    Louis E
    J Crohns Colitis; 2015 Jan; 9(1):1-3. PubMed ID: 25536671
    [No Abstract]   [Full Text] [Related]  

  • 2. The routine use of fecal calprotectin in clinical pediatric practice: almost there or still issues to address?
    Bourdillon G; Biskou O; MacKinder M; Khan MJ; Tsiountsioura M; Clark C; Russell RK; McGrogan P; Edwards CA; Gerasimidis K
    Am J Gastroenterol; 2013 Nov; 108(11):1811-3. PubMed ID: 24192960
    [No Abstract]   [Full Text] [Related]  

  • 3. FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms.
    Kotze LM; Nisihara RM; Marion SB; Cavassani MF; Kotze PG
    Arq Gastroenterol; 2015; 52(1):50-4. PubMed ID: 26017083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of fecal calprotectin in differentiating active inflammatory bowel disease from coexistent irritable bowel syndrome.
    Sprakes MB; Hamlin PJ; Ford AC
    Am J Gastroenterol; 2011 Jan; 106(1):166; author reply 166-7. PubMed ID: 21212757
    [No Abstract]   [Full Text] [Related]  

  • 5. [Assessment of fecal calprotectin concentration as inflammatory marker in inflammatory bowel diseases in children--preliminary report].
    Krzesiek E; Iwańczak B
    Pol Merkur Lekarski; 2010 Oct; 29(172):241-6. PubMed ID: 21207640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of a novel fecal marker--fecal tumor pyruvate kinase type M2 (M2-PK) with fecal calprotectin in patients with inflammatory bowel disease: a prospective study.
    Shastri YM; Povse N; Schröder O; Stein J
    Clin Lab; 2008; 54(9-10):389-90. PubMed ID: 19097497
    [No Abstract]   [Full Text] [Related]  

  • 7. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.
    Mooiweer E; Severs M; Schipper ME; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
    J Crohns Colitis; 2015 Jan; 9(1):50-5. PubMed ID: 25518048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interest of fecal calprotectine dosage in inflammatory bowel diseases, state of the art and perspectives.
    Chaabouni T; Manceau H; Peoc'h K
    Ann Biol Clin (Paris); 2016 Aug; 74(4):385-94. PubMed ID: 27492691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fecal Calprotectin as a Screening Marker for Inflammatory Bowel Disease.
    Sridhar M; Kesavelu D
    Indian Pediatr; 2019 Mar; 56(3):249-250. PubMed ID: 30955002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of calprotectin in irritable bowel syndrome and in inflammatory bowel disease.
    Grad C; David L; Portincasa P; Dumitraşcu DL
    Rom J Intern Med; 2012; 50(1):3-6. PubMed ID: 22788087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
    Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
    Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avoid Endoscopy in Children With Suspected Inflammatory Bowel Disease Who Have Normal Calprotectin Levels.
    Heida A; Holtman GA; Lisman-van Leeuwen Y; Berger MY; van Rheenen PF
    J Pediatr Gastroenterol Nutr; 2016 Jan; 62(1):47-9. PubMed ID: 26252922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Usefulness of Fecal Calprotectin in the era of the COVID-19 Pandemic.
    Mago S; Vaziri H; Tadros M
    Gastroenterology; 2021 Jun; 160(7):2623-2625. PubMed ID: 32425230
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunoanalytical characteristics of fecal calprotectin.
    Desbène C; Gaillard O; Kapel N
    Ann Biol Clin (Paris); 2016 Dec; 74(6):725-734. PubMed ID: 27848924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of fecal calprotectin test in the work-up of IBS patients.
    Delgado-Aros S; Cremonini F
    Gastroenterology; 2003 Apr; 124(4):1164-5. PubMed ID: 12671919
    [No Abstract]   [Full Text] [Related]  

  • 16. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease.
    Gisbert JP; McNicholl AG
    Dig Liver Dis; 2009 Jan; 41(1):56-66. PubMed ID: 18602356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The semi-quantitative calprotectin rapid test--is it useful in inflammatory bowel disease?
    Dranga M; Dumitrescu G; Badea M; Blaj A; Mihai C; Prelipcean CC
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(3):761-5. PubMed ID: 23272524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Faecal calprotectin in inflammatory bowel diseases: review].
    Kallel L; Fekih M; Boubaker J; Filali A
    Tunis Med; 2011 May; 89(5):425-9. PubMed ID: 21557177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome.
    Silberer H; Küppers B; Mickisch O; Baniewicz W; Drescher M; Traber L; Kempf A; Schmidt-Gayk H
    Clin Lab; 2005; 51(3-4):117-26. PubMed ID: 15819166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Calprotectin levels in patients with idiopathic inflammatory bowel disease comparison of two commercial tests].
    Malícková K; Janatková I; Bortlík M; Komárek V; Lukás M
    Epidemiol Mikrobiol Imunol; 2008 Nov; 57(4):147-53. PubMed ID: 19069028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.